Do analysts prefer SMTI or AVNS?

Sanara MedTech currently has a consensus target price of $35.00, suggesting a potential downside of 0.43%. Given Sanara MedTech's stronger consensus rating and higher probable upside, equities research analysts plainly believe Sanara MedTech is more favorable than Avanos Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sanara MedTech 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80 Avanos Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better valuation & earnings, CERS or SMTI?

Cerus has higher revenue and earnings than Sanara MedTech. Cerus is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cerus $206.13M 2.54 -$15.63M -$0.03 N/A Sanara MedTech $103.12M 3.13 -$37.56M -$3.59 N/A

Is CERS or SMTI more profitable?

Cerus has a net margin of -3.06% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 29.72% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets Cerus -3.06% -10.19% -3.14% Sanara MedTech -29.15% 29.72% 2.84%

Which has stronger earnings and valuation, EMBC or SMTI?

Embecta has higher revenue and earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Embecta $1.08B 0.29 $95.40M $1.48 3.77 Sanara MedTech $103.12M 3.13 -$37.56M -$3.59 N/A

Is EMBC or SMTI more profitable?

Embecta has a net margin of 8.59% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 29.72% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets Embecta 8.59% -19.25% 10.82% Sanara MedTech -29.15% 29.72% 2.84%

Sanara MedTech (SMTI) Competitors

$35.15 -0.13 (-0.37%)

Closing price 04:00 PM Eastern

Extended Trading

$35.14 -0.01 (-0.03%)

As of 04:15 PM Eastern

Compare

SMTI vs. AVNS, QDEL, CERS, EMBC, and OSUR

Should you buy Sanara MedTech stock or one of its competitors? Sanara MedTech's main competitors and comparable companies include Avanos Medical (AVNS), QuidelOrtho (QDEL), Cerus (CERS), Embecta (EMBC), and OraSure Technologies (OSUR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does Sanara MedTech compare to Avanos Medical?

Sanara MedTech (NASDAQ:SMTI) and Avanos Medical (NYSE:AVNS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Sanara MedTech has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market. Comparatively, Avanos Medical has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market.

Sanara MedTech has higher earnings, but lower revenue than Avanos Medical. Avanos Medical is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$103.12M	3.13	-$37.56M	-$3.59	N/A
Avanos Medical	$715.90M	1.64	-$72.90M	-$1.61	N/A

In the previous week, Avanos Medical had 1 more articles in the media than Sanara MedTech. MarketBeat recorded 1 mentions for Avanos Medical and 0 mentions for Sanara MedTech. Avanos Medical's average media sentiment score of 0.21 beat Sanara MedTech's score of 0.00 indicating that Avanos Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Sanara MedTech	Neutral
Avanos Medical	Neutral

Avanos Medical has a net margin of -10.39% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 29.72% beat Avanos Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-29.15%	29.72%	2.84%
Avanos Medical	-10.39%	5.39%	3.97%

8.1% of Sanara MedTech shares are held by institutional investors. Comparatively, 95.2% of Avanos Medical shares are held by institutional investors. 42.0% of Sanara MedTech shares are held by company insiders. Comparatively, 2.3% of Avanos Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Sanara MedTech currently has a consensus target price of $35.00, suggesting a potential downside of 0.43%. Given Sanara MedTech's stronger consensus rating and higher probable upside, equities research analysts plainly believe Sanara MedTech is more favorable than Avanos Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Avanos Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Avanos Medical beats Sanara MedTech on 8 of the 15 factors compared between the two stocks.

How does Sanara MedTech compare to QuidelOrtho?

Sanara MedTech (NASDAQ:SMTI) and QuidelOrtho (NASDAQ:QDEL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

Sanara MedTech has higher earnings, but lower revenue than QuidelOrtho. Sanara MedTech is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$103.12M	3.13	-$37.56M	-$3.59	N/A
QuidelOrtho	$2.73B	0.26	-$1.13B	-$15.41	N/A

Sanara MedTech presently has a consensus price target of $35.00, suggesting a potential downside of 0.43%. QuidelOrtho has a consensus price target of $13.63, suggesting a potential upside of 31.77%. Given QuidelOrtho's higher probable upside, analysts clearly believe QuidelOrtho is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, QuidelOrtho had 3 more articles in the media than Sanara MedTech. MarketBeat recorded 3 mentions for QuidelOrtho and 0 mentions for Sanara MedTech. QuidelOrtho's average media sentiment score of 0.45 beat Sanara MedTech's score of 0.00 indicating that QuidelOrtho is being referred to more favorably in the news media.

Company	Overall Sentiment
Sanara MedTech	Neutral
QuidelOrtho	Neutral

Sanara MedTech has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market. Comparatively, QuidelOrtho has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

Sanara MedTech has a net margin of -29.15% compared to QuidelOrtho's net margin of -39.20%. Sanara MedTech's return on equity of 29.72% beat QuidelOrtho's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-29.15%	29.72%	2.84%
QuidelOrtho	-39.20%	4.88%	1.63%

8.1% of Sanara MedTech shares are owned by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are owned by institutional investors. 42.0% of Sanara MedTech shares are owned by company insiders. Comparatively, 1.1% of QuidelOrtho shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Sanara MedTech beats QuidelOrtho on 9 of the 15 factors compared between the two stocks.

How does Sanara MedTech compare to Cerus?

Cerus (NASDAQ:CERS) and Sanara MedTech (NASDAQ:SMTI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

78.4% of Cerus shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 5.3% of Cerus shares are held by insiders. Comparatively, 42.0% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Cerus had 2 more articles in the media than Sanara MedTech. MarketBeat recorded 2 mentions for Cerus and 0 mentions for Sanara MedTech. Cerus' average media sentiment score of 0.51 beat Sanara MedTech's score of 0.00 indicating that Cerus is being referred to more favorably in the media.

Company	Overall Sentiment
Cerus	Positive
Sanara MedTech	Neutral

Cerus has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

Cerus has higher revenue and earnings than Sanara MedTech. Cerus is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$206.13M	2.54	-$15.63M	-$0.03	N/A
Sanara MedTech	$103.12M	3.13	-$37.56M	-$3.59	N/A

Cerus has a net margin of -3.06% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 29.72% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-3.06%	-10.19%	-3.14%
Sanara MedTech	-29.15%	29.72%	2.84%

Cerus currently has a consensus target price of $5.25, indicating a potential upside of 101.92%. Sanara MedTech has a consensus target price of $35.00, indicating a potential downside of 0.43%. Given Cerus' stronger consensus rating and higher possible upside, research analysts plainly believe Cerus is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

Cerus beats Sanara MedTech on 11 of the 15 factors compared between the two stocks.

How does Sanara MedTech compare to Embecta?

Embecta (NASDAQ:EMBC) and Sanara MedTech (NASDAQ:SMTI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

Embecta has a net margin of 8.59% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 29.72% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	8.59%	-19.25%	10.82%
Sanara MedTech	-29.15%	29.72%	2.84%

Embecta presently has a consensus target price of $11.00, suggesting a potential upside of 97.13%. Sanara MedTech has a consensus target price of $35.00, suggesting a potential downside of 0.43%. Given Embecta's higher possible upside, equities analysts plainly believe Embecta is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Embecta has higher revenue and earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08B	0.29	$95.40M	$1.48	3.77
Sanara MedTech	$103.12M	3.13	-$37.56M	-$3.59	N/A

In the previous week, Embecta had 4 more articles in the media than Sanara MedTech. MarketBeat recorded 4 mentions for Embecta and 0 mentions for Sanara MedTech. Embecta's average media sentiment score of 0.34 beat Sanara MedTech's score of 0.00 indicating that Embecta is being referred to more favorably in the media.

Company	Overall Sentiment
Embecta	Neutral
Sanara MedTech	Neutral

Embecta has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market.

93.8% of Embecta shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 1.3% of Embecta shares are held by insiders. Comparatively, 42.0% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Embecta beats Sanara MedTech on 10 of the 15 factors compared between the two stocks.

How does Sanara MedTech compare to OraSure Technologies?

OraSure Technologies (NASDAQ:OSUR) and Sanara MedTech (NASDAQ:SMTI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

Sanara MedTech has lower revenue, but higher earnings than OraSure Technologies. Sanara MedTech is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OraSure Technologies	$115.02M	2.39	-$68.73M	-$0.69	N/A
Sanara MedTech	$103.12M	3.13	-$37.56M	-$3.59	N/A

Sanara MedTech has a net margin of -29.15% compared to OraSure Technologies' net margin of -43.70%. Sanara MedTech's return on equity of 29.72% beat OraSure Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OraSure Technologies	-43.70%	-19.09%	-16.26%
Sanara MedTech	-29.15%	29.72%	2.84%

OraSure Technologies presently has a consensus target price of $3.00, suggesting a potential downside of 24.81%. Sanara MedTech has a consensus target price of $35.00, suggesting a potential downside of 0.43%. Given Sanara MedTech's stronger consensus rating and higher possible upside, analysts plainly believe Sanara MedTech is more favorable than OraSure Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OraSure Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

93.5% of OraSure Technologies shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 4.7% of OraSure Technologies shares are held by company insiders. Comparatively, 42.0% of Sanara MedTech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

OraSure Technologies has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

In the previous week, OraSure Technologies' average media sentiment score of 0.00 equaled Sanara MedTech'saverage media sentiment score.

Company	Overall Sentiment
OraSure Technologies	Neutral
Sanara MedTech	Neutral

Summary

Sanara MedTech beats OraSure Technologies on 9 of the 13 factors compared between the two stocks.

Get Sanara MedTech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SMTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SMTI vs. The Competition

Export

Metric	Sanara MedTech	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$323.03M	$5.52B	$7.21B	$13.10B
Dividend Yield	N/A	1.79%	2.53%	13.00%
P/E Ratio	-9.79	25.27	274.58	25.69
Price / Sales	3.13	43.07	639.38	80.65
Price / Cash	59.15	32.79	76.31	52.02
Price / Book	52.46	5.78	10.44	6.32
Net Income	-$37.56M	$151.55M	$3.49B	$359.73M
7 Day Performance	0.14%	1.49%	0.51%	1.35%
1 Month Performance	2.03%	-3.63%	-3.38%	-3.68%
1 Year Performance	6.19%	6.20%	16.04%	5.56%

Sanara MedTech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SMTI Sanara MedTech	0.5939 of 5 stars	$35.15 -0.4%	$35.00 -0.4%	+4.3%	$323.03M	$103.12M	N/A	108
AVNS Avanos Medical	0.1386 of 5 stars	$24.99 flat	N/A	N/A	$1.17B	$715.90M	N/A	4,040	Positive News
QDEL QuidelOrtho	3.5158 of 5 stars	$11.07 +4.1%	$13.63 +23.1%	-61.6%	$765.65M	$2.73B	N/A	6,500
CERS Cerus	1.6547 of 5 stars	$2.54 +1.4%	$5.25 +107.1%	+76.8%	$512.26M	$206.13M	N/A	345	Positive News
EMBC Embecta	3.3378 of 5 stars	$5.23 +2.7%	$11.00 +110.5%	-61.7%	$297.07M	$1.08B	3.54	1,850	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SMTI) was last updated on 9/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sanara MedTech (SMTI) Competitors

SMTI vs. AVNS, QDEL, CERS, EMBC, and OSUR

How does Sanara MedTech compare to Avanos Medical?

Summary

How does Sanara MedTech compare to QuidelOrtho?

Summary

How does Sanara MedTech compare to Cerus?

Summary

How does Sanara MedTech compare to Embecta?

Summary

How does Sanara MedTech compare to OraSure Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMTI vs. The Competition

Sanara MedTech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sanara MedTech (SMTI) Competitors

SMTI vs. AVNS, QDEL, CERS, EMBC, and OSUR

How does Sanara MedTech compare to Avanos Medical?

Which has more volatility and risk, SMTI or AVNS?

Which has better earnings and valuation, SMTI or AVNS?

Does the media favor SMTI or AVNS?

Is SMTI or AVNS more profitable?

Do insiders & institutionals hold more shares of SMTI or AVNS?

Do analysts prefer SMTI or AVNS?

Summary

How does Sanara MedTech compare to QuidelOrtho?

Which has preferable earnings and valuation, SMTI or QDEL?

Do analysts prefer SMTI or QDEL?

Does the media favor SMTI or QDEL?

Which has more volatility & risk, SMTI or QDEL?

Is SMTI or QDEL more profitable?

Do insiders and institutionals have more ownership in SMTI or QDEL?

Summary

How does Sanara MedTech compare to Cerus?

Do insiders & institutionals hold more shares of CERS or SMTI?

Does the media refer more to CERS or SMTI?

Which has more risk & volatility, CERS or SMTI?

Which has better valuation & earnings, CERS or SMTI?

Is CERS or SMTI more profitable?

Do analysts recommend CERS or SMTI?

Summary

How does Sanara MedTech compare to Embecta?

Is EMBC or SMTI more profitable?

Do analysts rate EMBC or SMTI?

Which has stronger earnings and valuation, EMBC or SMTI?

Does the media refer more to EMBC or SMTI?

Which has more risk and volatility, EMBC or SMTI?

Do institutionals and insiders hold more shares of EMBC or SMTI?

Summary

How does Sanara MedTech compare to OraSure Technologies?

Which has higher earnings and valuation, OSUR or SMTI?

Is OSUR or SMTI more profitable?

Do analysts rate OSUR or SMTI?

Do institutionals & insiders hold more shares of OSUR or SMTI?

Which has more volatility & risk, OSUR or SMTI?

Does the media prefer OSUR or SMTI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMTI vs. The Competition

Sanara MedTech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools